Tesofensine vs semaglutide

Tesofensine (B-tier) vs semaglutide (S-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

Tesofensine · tier B

Tesofensine is an investigational monoamine-reuptake inhibitor with randomized oral weight-loss evidence and a material integrity caveat attached to its central trial report.

Tesofensine produced dose-related 24-week weight loss in TIPO-1 and in a Mexican regulator-registry summary. The first report has an Expression of Concern, the phase 3 summary is not a peer-reviewed full report, and no final Mexican or US authorization was verified.

Expression of Concern attached to the central TIPO-1 report · half-life model-derived terminal values of about 234 h for parent and 374 h for M1 in the cited Alzheimer-disease population · weight loss

semaglutide · tier S

A GLP-1 receptor agonist with current US injection and oral products for distinct labeled uses.

Strong obesity, cardiovascular, kidney, and MASH evidence, but each result belongs to its own product, route, population, and label.

14.9% STEP 1 mean weight change · half-life ~1 week · weight loss

at a glance

• Tesofensine: tier B · Expression of Concern attached to the central TIPO-1 report
• semaglutide: tier S · 14.9% STEP 1 mean weight change

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.